TrialJournal of neuro-oncology2011

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

Nancy U Lin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.